Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 775 shares of Beta Bionics stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $17.35, for a total value of $13,446.25. Following the transaction, the insider owned 55,334 shares in the company, valued at approximately $960,044.90. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Mark Hopman also recently made the following trade(s):
- On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
- On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total value of $619,581.27.
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total value of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $101,798.97.
Beta Bionics Stock Performance
Shares of NASDAQ BBNX traded down $0.96 during trading on Friday, hitting $16.35. 660,831 shares of the company were exchanged, compared to its average volume of 1,176,239. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The company has a fifty day moving average price of $19.04 and a 200-day moving average price of $15.19. The firm has a market capitalization of $735.59 million, a PE ratio of -9.91 and a beta of 3.39.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The firm had revenue of $32.01 million during the quarter. Research analysts anticipate that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.
Trending Headlines about Beta Bionics
Here are the key news stories impacting Beta Bionics this week:
- Negative Sentiment: Multiple law firms announced or promoted a securities class action against Beta Bionics and certain executives on behalf of investors who purchased shares from July 30, 2025, through February 24, 2026. The lawsuit alleges that the company misled investors about its automated insulin-delivery system, iLet, and related operational and compliance issues. Hagens Berman class-action announcement
- Negative Sentiment: The allegations follow reported FDA concerns involving the iLet system, including claims that Beta Bionics abandoned a built-in safety feature for the dosing algorithm and failed to investigate more than 18,000 customer complaints. The articles state that successive revelations contributed to a roughly 72% decline in the stock during the relevant period. These claims have not been proven in court. SueWallSt shareholder notice
- Negative Sentiment: Investors have until November 3, 2026, to seek appointment as lead plaintiff. The growing number of law-firm solicitations increases visibility around potential litigation costs, reputational damage, regulatory uncertainty and possible disruption to the company’s iLet business, all of which may keep volatility elevated. Kaplan Fox deadline announcement
Analysts Set New Price Targets
Several research firms have weighed in on BBNX. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Robert W. Baird raised their price target on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. Truist Financial lifted their price target on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Leerink Partners upped their price objective on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, September 14th. Finally, Barclays assumed coverage on Beta Bionics in a report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.
Read Our Latest Report on Beta Bionics
Institutional Trading of Beta Bionics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Beta Bionics during the second quarter worth $52,340,000. Eversept Partners LP grew its stake in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares in the last quarter. 12 West Capital Management LP acquired a new stake in shares of Beta Bionics in the fourth quarter valued at $17,520,000. Bruce & Co. Inc. acquired a new stake in shares of Beta Bionics in the first quarter valued at $5,518,000. Finally, Bank of America Corp DE purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at $8,566,000.
About Beta Bionics
Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.
The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.
Featured Articles
- Five stocks we like better than Beta Bionics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
